ストックスクリーナーアプリを入手
3.22
0.62%
-0.02
アフターアワーズ：
3.26
0.04
+1.24%
前日終値:
$3.24
開ける：
$3.21
24時間の取引高:
1.29M
Relative Volume:
2.04
時価総額：
$206.45M
収益：
-
当期純損益:
$-27.03M
株価収益率:
-5.75
EPS:
-0.56
ネットキャッシュフロー:
$-23.97M
1週間 パフォーマンス:
+6.27%
1か月 パフォーマンス:
-25.29%
6か月 パフォーマンス:
-57.41%
1年 パフォーマンス:
+130.00%
1日の値動き範囲:
$3.15
$3.32
1週間の範囲:
$3.02
$3.365
52週間の値動き範囲:
$1.39
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
863 MITTEN ROAD, BURLINGAME, CA
CRVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
3.22 | 206.45M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-02 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-18 | 開始されました | Oppenheimer | Outperform |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-05-29 | 開始されました | ROTH Capital | Buy |
| 2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 開始されました | Credit Suisse | Outperform |
| 2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister
Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com
Corvus Pharmaceuticals expands board with new director - Investing.com Australia
Corvus Pharmaceuticals Appoints New Director to Board - TipRanks
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - TradingView
Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan
Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN
Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada
Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - Greenwich Time
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India
Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq
CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter
Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times
New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
Corvus Pharma Reveals Autoimmune Pipeline Strategy at Major HC Wainwright Conference - Stock Titan
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - The Manila Times
Corvus Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
Corvus Pharmaceuticals Reveals Q4 Earnings Date: Complete Financial Picture Coming March 25 - StockTitan
Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday - The AM Reporter
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) - The Manila Times
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for ... - The Bakersfield Californian
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with - EIN News
Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts - Armenian Reporter
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):